Alpha Cognition Reports Strong FY25 Revenue of $10.2M, ZUNVEYL Sales Up 62% QoQ
Summary
Alpha Cognition Inc. reported robust fiscal year 2025 financial results, with total revenue reaching $10.2 million, including $6.8 million in ZUNVEYL net product revenue. The company demonstrated strong commercial execution for ZUNVEYL, with fourth-quarter bottles dispensed increasing 62% quarter-over-quarter to 4,941. Additionally, Alpha Cognition secured a second national PBM contract, expanding market access for ZUNVEYL. The company ended the year with a solid cash position of $66 million, supporting its target of operational profitability in 2027 and ongoing clinical studies. This positive update on commercial momentum and financial health is material for a company of this size and provides a strong indication of progress for its key Alzheimer's treatment.
At the time of this announcement, ACOG was trading at $5.19 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $112.8M. The 52-week trading range was $3.75 to $11.54. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.